Zura Bio (ZURA) AI Stock Analysis

• Market Cap: $375.18M
• Dividend Yield: N/A
• Average Volume (3M): 2.99M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.39
• Revenue Growth: N/A
• EPS Growth: -19.69%
• Country: US
• Employees: 30
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.21
• Shares Outstanding: 65,023,310
• 10 Day Avg. Volume: 1,304,161
• 30 Day Avg. Volume: 2,987,270
• PEG Ratio: 0.05
• Price to Book (P/B): 1.28
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -6.67
• Enterprise Value/Market Cap: 0.67
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: -10.07K
• Enterprise Value/Ebitda: -3.65
• 1Y Price Target: $19.67
• Price Target Upside: 211.23% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 57 Neutral
• Price Target: $6.00 ▼(-5.06% Downside)

Score is held back primarily by weak financial performance (pre-revenue, widening losses, and significant cash burn), partially offset by strong technical momentum and positive corporate updates supporting clinical progress and a stated funding runway through 2027. Valuation signals remain constrained by unprofitability and lack of dividend data.

Positive Factors

Advanced bispecific pipeline

A differentiated dual-pathway bispecific (tibulizumab) with Phase 2 studies and slated readouts provides structural de-risking potential. Successful clinical data would materially strengthen the company’s long-term commercial prospects and redress the typical binary risk of single-pathway biologics.

Near-term funding runway to key milestones

A disclosed cash position and runway through 2027 meaningfully reduce near-term dilution risk and enable the company to fund pivotal data generation. This allows management to focus on clinical execution and readouts rather than immediate financing, improving the odds of reaching value-creating milestones.

Low financial leverage

Zero reported debt and positive equity provide structural flexibility: lower interest burden, fewer covenant constraints, and clearer options for raising capital (equity, partnerships). This balance-sheet profile supports ongoing R&D spending without immediate interest expense pressure.

Negative Factors

Pre-revenue, widening losses

The company remains pre-revenue with materially negative net income, meaning profitability is contingent on clinical success and eventual commercialization. This structural unprofitability elevates dilution risk and makes long-term shareholder value highly dependent on trial outcomes rather than operating leverage.

Persistent high cash burn

Sustained negative operating and free cash flows indicate the business is not self-funding and will likely need external capital before commercialization. Continued burn erodes equity, constrains optionality for expanding programs, and raises the probability of financing-driven dilution or deal-making on unfavorable terms.

Governance and leadership turnover

Recent CEO change, a director resignation, and a board-led internal review that reset agreements signify governance disruption. Such structural leadership shifts can slow strategic execution, introduce direction changes, and create uncertainty for partners and investors during a period when consistent clinical development execution is critical.

Zura Bio Business Overview & Revenue Model

Company Description

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

How the Company Makes Money

Zura Bio generates revenue through the development and commercialization of its proprietary drug candidates. The company's primary revenue streams include licensing agreements, partnerships with other pharmaceutical companies, and potential sales of successfully developed therapies. Zura Bio collaborates with strategic partners for clinical development, regulatory approval, and distribution of its products, which can result in milestone payments and royalties. Additionally, the company may engage in research and development collaborations that provide funding and resource sharing to advance its product pipeline.

Zura Bio Financial Statement Overview

Summary

Early-stage profile with 0 revenue, widening losses (TTM net income about -$62.5M) and elevated cash burn (TTM operating/FCF about -$53M). Offsetting strengths include 0 debt and still-positive equity (~$108M), but ongoing burn is eroding the equity base.

Income Statement

Zura Bio is still pre-revenue (revenue is 0 across periods), and losses have widened in TTM (Trailing-Twelve-Months) with net income of about -$62.5M versus roughly -$52.4M in 2024. Profitability is structurally weak given the lack of revenue base, and margins are not meaningful/are distorted by near-zero revenue. A positive note is that the company carries no debt in recent periods, which reduces interest-related pressure, but overall earnings quality remains very weak at this stage.

Balance Sheet

The balance sheet is mixed but comparatively stronger than the income statement: total debt is 0 in 2023–TTM, and equity remains positive in TTM (~$108.2M). However, equity has declined from 2024 (~$146.8M) to TTM, consistent with ongoing losses, and return on equity is materially negative in TTM (about -0.52), signaling continued value dilution. Overall leverage risk looks low, but the trajectory shows burn-driven erosion of the equity base.

Cash Flow

Cash generation is weak: operating cash flow is negative and worsening (about -$53.4M in TTM versus -$28.1M in 2024), and free cash flow is also negative (about -$53.5M in TTM). While TTM free cash flow growth is shown as positive (~22%), it is improving from a still-deeply negative base, so the business remains reliant on external funding. A modest positive is that free cash flow broadly tracks reported losses (free cash flow to net income ~1.0), but the absolute cash burn level is high.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	-25.00K	0.00	0.00	0.00	0.00
EBITDA	-68.94M	-55.18M	-62.64M	-27.16M	8.42M
Net Income	-62.52M	-52.40M	-60.36M	-25.74M	8.42M
Balance Sheet
Total Assets	143.94M	179.53M	100.84M	5.26M	140.55M
Cash, Cash Equivalents and Short-Term Investments	139.02M	176.50M	99.81M	1.57M	729.22K
Total Debt	0.00	0.00	0.00	7.76M	0.00
Total Liabilities	25.49M	19.51M	21.29M	27.32M	10.35M
Stockholders Equity	108.24M	146.81M	59.33M	-32.06M	130.20M
Cash Flow
Free Cash Flow	-53.50M	-28.15M	-23.05M	-13.20M	-1.10M
Operating Cash Flow	-53.36M	-28.08M	-15.05M	-1.20M	-1.10M
Investing Cash Flow	-141.00K	-5.08M	-8.00M	-12.00M	-139.38M
Financing Cash Flow	4.30M	109.84M	121.29M	14.77M	141.21M

Zura Bio Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 6.32
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ZURA, the sentiment is Positive. The current price of 6.32 is above the 20-day moving average (MA) of 5.62, above the 50-day MA of 4.76, and above the 200-day MA of 2.76, indicating a bullish trend. The MACD of 0.39 indicates Positive momentum. The RSI at 63.08 is Neutral, neither overbought nor oversold. The STOCH value of 60.52 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ZURA.

Zura Bio Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PBYI	76 Outperform	$343.67M	9.59	39.69%	―	-12.96%	56.02%
ZURA	57 Neutral	$375.18M	-8.93	-47.85%	―	―	-19.69%
VTYX	57 Neutral	$1.00B	-9.30	-45.35%	―	―	36.65%
CLLS	54 Neutral	$280.97M	-10.59	-31.07%	―	158.54%	66.90%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
VOR	50 Neutral	$280.24M	-0.03	―	―	―	-1072.48%
PRQR	42 Neutral	$163.29M	-3.48	-99.45%	―	-11.99%	-42.04%

Zura Bio Corporate Events

Zura Bio Updates Outlook and Clinical Development Plans

On January 12, 2026, Zura Bio Limited released an updated corporate presentation and a press release detailing corporate and clinical trial developments, including its outlook for 2026. The company highlighted ongoing Phase 2 studies of its lead dual-pathway antibody tibulizumab in hidradenitis suppurativa and systemic sclerosis, noted expected topline data readouts in late 2026 and the first half of 2027, and emphasized that its current cash position of $139 million as of September 30, 2025 is expected to support operations through 2027, underscoring its funding runway through key clinical milestones.

The most recent analyst rating on (ZURA) stock is a Hold with a $5.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.

Zura Bio resets key agreements after internal review

On December 29, 2025, Zura Bio Limited entered into a new Letter Agreement with Athanor Capital and, on the same date, executed settlement and release agreements with Stone Peach and BAFFX17, terminating all outstanding agreements with those parties and securing broad releases of claims in favor of Zura Bio, its subsidiaries and affiliates. Following an internal review conducted by an independent Audit Subcommittee, which was formed and reported on in 2025, the board determined that replacing the Stone Peach arrangements with the Athanor Agreement was more commercially advantageous for the company and its shareholders, and that voiding or terminating the Stone Peach and BAFFX17 agreements would cleanly reset those relationships without financial restatements or findings of employee misconduct; the company now plans incremental enhancements to its internal controls and disclosure procedures that are not expected to materially alter its existing control framework.

The most recent analyst rating on (ZURA) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.

Zura Bio Director Resignation Sparks Governance Adjustments

On December 11, 2025, Arnout Ploos van Amstel resigned from Zura Bio Limited’s Board of Directors, effective immediately. His departure also includes resignation from the Nominating and Governance Committee of the Board and was not due to any disagreement regarding the company’s operations, policies, or practices. This change is likely to prompt adjustments in the company’s governance structure, given the loss of contribution from a key board member.

The most recent analyst rating on (ZURA) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Zura Bio stock, see the ZURA Stock Forecast page.